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It is now believed that possession of the human retinoblas-
toma susceptibility gene (Rb1) on the long arm of
chromosome 13 (band 14q) confers the hereditary basis for
this disease (Sparkes et al., 1983; Friend et al., 1986; Lee et
al., 1987; Fung et al., 1987). The presence of this gene in all
retinal cells gives an increased risk of developing retinoblas-
toma. A somatic event then leads to the development of a
retinoblastoma (Knudson 1971). It is characteristic of
patients with hereditary retinoblastoma that they present at
an early age (most frequently during the first 12 months of
life) and that they develop multiple tumours (usually
bilateral). Sporadic cases (excluding new genetic mutations to
Rbl positivity) tend to have solitary retinoblastoma and to
present at a slightly older age. It is perhaps better to think of
hereditary cases as being at risk of multiple tumours within
the whole retinal 'field' rather than the risk confined to the
contralateral eye - as all retinal areas are at risk.
Established retinoblastomas are usually curable by focal
treatment methods or external beam radiotherapy when they
are diagnosed at an early stage. More advanced intraocular
growths are curable only by enucleation, whilst metastatic
disease is often fatal. All treatment modalities carry mor-
bidity, but a sophisticated lens sparing external beam
radiotherapy method developed in the 1980's (Schipper 1983;
Harnett et al., 1987) has proved to be much less morbid than
previous external beam radiotherapy methods.
As early as 1963, Reece recognised the risk of multifocality
and advocated the irradiation of the whole retina bearing a
retinoblastoma (Reece, 1963). With the whole eye external
beam radiotherapy methods available at that time, Bedford
et al. (1971) concluded that any such prophylactic effect of
radiotherapy on new primary tumours could hardly be
justified due to the morbidity of treatment, (cataracts, dry
eye). However, the St. Bartholomew's whole eye radiotherapy
data reported by Bedford et al. (1971) did give the first
suggestion of a prophylactic effect of radiotherapy against
the clinical development of new primary tumours:- thus, of
63 eyes treated by focal methods, 12 (20%) developed new
primary tumours (with an average latency to clinical diag-
nosis of 4 months), whereas of 58 eyes treated by whole eye
radiotherapy, only five (8%) developed new primaries (after
an interestingly longer average latency of 10 months). These
data were obtained from unselected patients.
If the risk of a retina developing retinoblastoma could be
shown to be exceedingly high and if it could be shown that
low-morbidity (safe) retinal radiotherapy conferred a pro-
phylactic role, and if external beam radiotherapy (with a
similar external beam path/integral dose to the head) was
anyway indicated for treatment of the contralateral eye, then
it could be justified to direct the beam laterally to encompass
both retinae.
The index case infant in this manuscript was indisputedly
at high risk of developing retinoblastomas in her second
(apparently unaffected) retina, when at the age of 14 weeks,
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she required external beam radiotherapy for a posterior polar
retinoblastoma of her presenting eye. By the St. Bar-
tholomew's Hospital lens-sparing technique (Harnett et al.,
1987) the treatment portal would normally have been
directed away from the contralateral eye. Instead, following
acceptance of the logical development of the syllogism just
posed, we treated both retinae through opposed, direct
lateral portals. The syllogism is developed from raw data in
this manuscript before the index case is presented and then
the use of prophylactic retinal radiation in such an infant is
discussed and defended.
On the risk of subsequent retinoblastoma following whole eye
or whole retinal radiotherapy
Thirty-three infants developing retinoblastoma in the first 6
months of life and all with one parent affected by the disease,
were chosen as the high risk cohort suitable for study, in the
context of risk-discussion with regard to the index case.
Forty-four eyes from these 33 patients received whole eye or
whole retinal (i.e. lens-sparing retinal) radiotherapy in the
first 6 months of life. With a minimum of one year's follow-
up, (median more than 2 years), there were eight failures
within these 44 eyes. Of these failures, two were failures to
control the original primary Tumour(s). The other six
failures were due to new primary tumours. Of these six
failures, two occurred in one patient who developed new
tumours bilaterally at the ora serrata 1-2 years after lens-
sparing radiotherapy; (it is suspected that this child was
underdosed at these areas, but he is scored as new tumour
'failures' with regard to statistics in this manuscript). Four
other patients developed new tumours in the irradiated
retinae, (1, 4, 9 and 26 months after radiotherapy) of which
three eyes were successfully salvaged by focal methods and
the fourth was enucleated.
Thus the new tumour risk for infants with hereditary
retinoblastoma presenting in the first 6 months of life, whose
eyes are treated by external beam retinal radiotherapy is 6/44
(14%). This may be the worst case estimate, because of the
ora serrata failures. Overall 8/44 (18%) required salvage
therapy.
On the risk of subsequent retinoblastoma in the unirradiated
eye
Part A Selected infants aged less than 6 months
Amongst the 33 infants discussed in section I, there were 14
who had one eye irradiated and whose other eye at presenta-
tion was ophthalmologically normal (12 cases) or treated by
xenon or cryotherapy (two cases) - not radioactive plaque.
These 14 are hereafter referred to as 'control' eyes. In the
other 19 cases, the contralateral eye was either enucleated or
irradiated.
Two of the 14 patients never developed a retinoblastoma
in the control eye. The other 12 patients all subsequently
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developed retinoblastomas in their 'control' eyes. A total of
30 new tumours were detected in these 12 'control' eyes. This
number may be an underestimate of the incidence risk of new
tumours as seven of the 12 went on to receive external beam
radiotherapy (whole eye or retinal only) to the control eye
during the period of risk.
The risk of the control eye developing retinoblastoma in
this cohort of patients is 12/14 (86%). Another relevant
statistic is that the overall incidence of bilateral retinoblas-
toma in the first 6 months of life in this patient group was
31/33 (94%).
Part B Infants less than 12 months
A less 'selected' group of patients was also studied. Infants of
less than 12 months of age, presenting between June 1970
and June 1992 were studied. Of 182 infants presenting during
the first year of life, 125 (69%) presented with bilateral
disease and of these 43 (24% of total) had a positive family
history. Fifty-seven (31%) presented with unilateral disease
of whom 20 (35%) had a positive family history. Fifteen of
the latter 20 patients (75%) developed (new) retinoblastomas
in the contralateral eye with a median latency of 3 months
(range 1 -11 months) from the diagnosis of the first
primary.
Sixteen of the 37 family history negative patients with
unilateral disease developed new tumours in the contralateral
eye (43%). Of the 21 other family history negative patients
who did not develop contralateral tumours, 16 underwent
enucleation of the presenting eye. However, in the five who
were not enucleated, no new tumours were observed in the
presenting eye.
For the development of the posed syllogism, one may
conclude that, from this less selected patient study group, the
risk of developing a retinoblastoma in the contralateral
retina, for an infant with one retinoblastoma and a positive
family history, is not less than 75%. This is almost certainly
an underestimate because of the high 'bilateral' rate in this
series due to early ophthalmological diagnosis of metach-
ronous bilateral tumours at presentation.
Collateral data obtained from this cohort of patients relate
to the overall need for enucleation and the overall incidence
of failure of external beam radiotherapy to control int-
raocular retinoblastoma. Of the 182 patients (with 338 eyes
developing retinoblastoma), there were 120 ocular enuclea-
tion operations (36%). Of the 338 affected eyes, 134 received
external beam radiotherapy at some time point. Subsequent
to radiotherapy, 36 of these 134 patients required some form
of salvage therapy (27%).
On the therapeutic success rate and lack of morbidity of the
St. Bartholomew's lens-sparing radiotherapy method
Between May 1985 and September 1987, 55 eyes in 44 child-
ren underwent lens-sparing, external beam, retinal
radiotherapy for retinoblastoma at St. Bartholomew's Hos-
pital. This was the first group of patients receiving this
treatment and it is the group with the longest follow-up. The
method has been previously described (Harnett et al., 1987).
The indications for this technique were:- Reece-Ellsworth
Group I - III tumours, posterior pole or macular/papillary
tumours, any single retinoblastoma greater than 13 mm or an
eye with more than two tumours otherwise amenable to
radioactive plaque treatment. Contraindications were
vitreous seeding and active tumours within 3 mm of the ora
serrata; any retinal detachment extending to the ora was also
an exclusive characteristic. A dose of 4000cGy in 20 frac-
tions over 4 weeks was delivered by the 6 MV xray technique
in all cases.
All 44 patients have been followed by serial EUA's. Of the
55 eyes, there have been 18 failures (33% relapse rate): 13
eyes with new tumours and five with local recurrences. This
figure is slightly higher than the 27% quoted in section IIB.
Of the 13 eyes with new tumours, 12 developed at or anterior
to the equator where the radiation dose starts to fall; (all but
two of the eyes with new tumours were successfully salvaged
by focal therapies). Five eyes required enucleation for failure
to control tumour (three with local recurrences, two with
refractory new tumours) - none for a Stage I tumour at
presentation.
In the follow-up of these 55 eyes, two children who
required plaque therapy in addition to lens-sparing
radiotherapy are the only two with posterior subcapsular lens
opacities and there are no children with dry-eye syndrome.
Growth retardation in the temporal regions is now visible
following 5 years' follow-up.
On the facility of controlling early stage disease
Between January 1970 and December 1985, 175 eyes in 142
children underwent external beam radiotherapy at this centre.
Their follow-up has been analysed (Hungerford et al., 1991).
These patients were treated before lens-sparing technology
became available at this centre. The radiotherapy prescrip-
tions varied, mainly due to the strictures posed by repeated
general anaesthesia (Hungerford et al., 1991).
Table I lists the failure rate of primary external beam
radiotherapy in each Reece and Ellsworth group. It should
be noted that it is customary in this hospital to place all cases
with vitreous seeding into Stage V and this has 'artificially'
improved the Stage V results. Apart from this apparent
anomaly, it seems clear that radiotherapy is more likely to
sterilise early stage tumours.
The index case
This child was referred to this hospital at age 14 weeks with
the following family history: her mother had suffered
bilateral retinoblastoma at an early age being treated by right
enucleation and left radium plaque at this hospital. The
mother had conceived triplets in her only pregnancy by IVF.
Unfortunately one of the triplets died in utero and examina-
tion of the dead foetus demonstrated bilateral retinoblas-
toma. The mother gave birth to two live born children. By
the age of 3 months both children had developed retinoblas-
toma - one in both retinae (a single 1.5 mm tumour in the
right eye and two, 1 mm and 10 mm diameter, tumours in
the left eye). The second child - our index case - had four
tumours in the left retina (1 mm, 2 mm, 5 mm and 5 mm
diameters) with no evidence of raised pressure, retinal detach-
ment nor vitreous seeding. The right eye was unaffected at
this time. All three affected eyes were staged as Reece Group
I.
Both twins were treated by the St. Bartholomew's lens-
sparing retinal radiotherapy technique to both retinae,
(4000 cGy T.D. - 20 fractions over 28 days by opposed
lateral 6 MV xray portals).
Follow-up of our index case child has demonstrated no
recurrence of the four tumours in the left eye and no new
tumours in either eye, now at 2 years post-treatment.
With regard to morbidity, there are retinal pigment
epithelium changes at the posterior pole of the left eye and
she squints medially in bright light. Her vision will probably
not be normal in this eye. Her right eye appears normal - at
2 years from treatment.
Table I Effect of Reece Ellsworth Group on response
Overall success
Reece Failure rate Salvage rate rate including
Ellsworth of primary offailures salvage by
Group radiotherapy by focal therapy focal therapy
I 2/16 (13%) 2/2 (100%) 16/16 (100%)
II 24/55 (44%) 15/24 (62%) 46/55 (84%)
III 28/68 (41%) 16/28 (57%) 56/68 (82%)
IV 6/7 (85%) 2/6 (34%) 3/7 (43%)
V 16/29 (56%) 6/16 (37%) 19/29 (66%)PROPHYLACTIC RETINAL RADIOTHERAPY 745
Discussion
To recommend prophylactic retinal radiotherapy for a
disease in which the occurrence of radiogenic second cancers
is perhaps as well established as in any other must be
justified. However, a syllogism was posed in the introduction
and raw data have now been presented to defend the use of
prophylactic retinal radiotherapy in our index case.
For an infant with an affected parent, and who develops
retinoblastoma in one eye within the first 6 months of life,
the risk of the second retina developing tumours is by cal-
culations performed here on 14 control eyes, 86%; (by an
alternative calculation the risk of bilaterlity was 94%). Tak-
ing a larger group of positive family history infants presen-
ting with unilateral disease in their first year, it was cal-
culated that there is at least a 75% risk of the second retina
developing retinoblastoma. This latter statistic may well be
artefactually low because of the high number of bilateral but
metachronous tumours picked up by expert ophthalmic
assessment of both eyes.
In the study group of 33 infants deemed comparable to
our index case, the new tumour risk following external beam
radiotherapy was 14% although, overall, 18% required sal-
vage therapy. These figures are better than our overall
experience of 27% ofpatients requiring some form of salvage
therapy after external beam radiotherapy and of the 33%
figure from our first long term follow-up cohort of lens-
sparing radiotherapy patients.
The question then arises as to whether reduction in the risk
of new tumours from 75-86% to 14-35% can justify pro-
phylactic radiotherapy. Before the introduction of modern,
accurate, lens-sparing retinal radiotherapy, there is little
doubt that prophylactic radiotherapy would have been later
followed by unacceptable morbidity. However, in the late
follow-up of our first cohort of patients treated by the
modern method, there have been no cataracts nor 'dry-eye'
complications. Of course, there will be growth abnormalities
of the bony orbits on both sides following bilateral ocular
radiotherapy and a chance of late radiogenic second cancer,
although this last being more closely linked to RB-1 gene
possession. However, in a child who was anyway to receive
external beam radiotherapy to one eye, and in whom a
x-radiation path would therefore traverse the head whether
angled obliquely cranio-caudal or obliquely caudo-cranially,
we would argue that the risk of a late radiogenic second
cancer would not be increased. Furthermore, bearing in mind
our overall experience that 40% of all patients presenting
with retinoblastoma at this centre require external beam
radiotherapy and that seven of the 14 (50%) of the control
eyes in the patients described in Section I subsequently
required external beam radiotherapy, we can say that there is
at least a 40-50% chance that external beam radiotherapy
would be later needed - hence a second radiation path
traversing the head and increasing the integral dose. This
being the case, there is an approximate one in two chance
that the integral radiation dose to the child's head, and hence
the risk of late radiogenic second cancer, would actually be
considerably greater if the radiotherapy to the second eye is
delayed. (The extra 20 general anaesthetic sessions is worthy
of minor extra note).
Also relevant to this discussion is the fact that sterilisation
of early tumours (Stage I) is easier than that of later stage
tumours. It would seem a reasonable extrapolation to
presume, and indeed it is born out by the data in Sections I
and II, that preclinical tumours are more easily sterilised
than clinically apparent ones.
The use of the term 'preclinical tumours' opens the discus-
sion as to what the radiotherapy is actually doing in this
'prophylactic role'. Although we have no evidence to support
either supposition, we favour the hypothesis that
radiotherapy is sterilising a tumour that has not yet grown to
a size large enough to be clinically apparent rather than
preventing the nascent event.
In conclusion, we have developed a syllogism that certain
very high risk infants can be identified whose retinae are
highly likely to be affected by retinoblastoma and for whom
radiotherapy has a prophylactic effect. Given the proven
ocular safety of modern radiotherapy technology and the
greater success in sterilising early rather than late tumours,
we feel the management of the index case was justified and
would be indicated for a similar high risk infant in the
future.
It is with great pleasure that we acknowledge the assistance of Dr C.
McLean and Mr N. Toma in the preparation of Section IIB and we
thank Miss T. Cocks for secretarial assistance.
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